Discover & Measure
Low-Abundance Biomolecules

The future of medicine will be shaped by the ability to reveal & understand biology more profoundly than ever before.
Studying blood

Studying blood

Harnessing blood as the most data rich sample type.
Discovering

Discovering

Discovering low abundance markers of disease
Developing

Developing

Developing assay against the most biologically significant markers of disease.
To achieve this breakthrough,

YYZ Pharmatech has created enabling technologies that overcome three fundamental challenges:

Harness blood as the most data rich sample type

Harness blood as the most data rich sample type

Identify low-abundance markers of disease

Identify low-abundance markers of disease

Develop ultra-sensitive assays against the most biologically significant biomolecules

Develop ultra-sensitive assays against the most biologically significant biomolecules

Platform

YYZ’s integrated technology platform identifies & quantifies low-abundance markers from blood. Supported by over 20 years of research & peer-reviewed publications, YYZ’s platform is powered by
bt_bb_section_top_section_coverage_image
https://yyzpharmatech.com/wp-content/uploads/2022/09/DPiPSA-1-1.png
Database-Driven Proteome Intact Partition Statistical Analysis

DPiPSA™ for Discovery

Discover low-abundance & biologically significant peptides & proteins from blood or other biological samples using an unbiased & statistically rigorous bioinformatics platform. DPiPSA’s innovation is based on the novel integration of optimized sample preparation, LC-MS/MS & classical statistics.

DPiPSA is:

  • Unbiased
  • Statistically Rigorous
  • Complementary to “omic” Methods

Applications:

  • Discover New Markers for Diagnostics & Prognostics
  • Identify New Therapeutic Targets
  • Identify Protein Modifications & Processing
  • Enable Multi Centered Clinical Drug Trials
bt_bb_section_bottom_section_coverage_image
Enzyme Linked Mass Spectrometric Assay

ELiMSA™ for Measurement

Assay low-abundance biomolecules using a quantitative detection method that reaches single molecule level sensitivity. ELiMSA’s innovation is based on the novel combination of enzyme amplification & LC-MS/MS.

ELiMSA is:

  • Ultra-Sensitive
  • Versatile
  • Easy to Execute

Applications:

  • Circulating Proteins & Peptides
  • Cell-Surface Receptors
  • DNA
  • RNA
https://yyzpharmatech.com/wp-content/uploads/2022/09/elimsa-1-2-1.png
https://yyzpharmatech.com/wp-content/uploads/2022/09/elimsa-1-2-1.png
Enzyme Linked Mass Spectrometric Assay

ELiMSA™ for Measurement

Assay low-abundance biomolecules using a quantitative detection method that reaches single molecule level sensitivity. ELiMSA’s innovation is based on the novel combination of enzyme amplification & LC-MS/MS.

ELiMSA is:

  • Ultra-Sensitive
  • Versatile
  • Easy to Execute

Applications:

  • Circulating Proteins & Peptides
  • Cell-Surface Receptors
  • DNA
  • RNA

Company

YYZ Pharmatech is emerging from stealth after nearly two decades pushing the frontiers of the discovery & measurement of biomolecules.
Business-Collection
Expertise
Co-founded by Dr. John G. Marshall, a leader in blood-based protein & ligand analytical biochemistry.
Business-Collection
Endurance
Co-founded & backed by two visionary family offices who specialize in building transformative platform technologies.
CollaborationToronto Metropolitan University spinout (formerly Ryerson University), with numerous clinical & academic partnerships.
bt_bb_section_bottom_section_coverage_image
Research & Publications

DPiPSA

The Plasma Peptidome

  • Largest number of blood proteins identified to date
  • Ability to monitor ex vivo proteolysis of most human proteins, including interleukins, from blood

Clinical Proteomics

View Publication 

Oncology: The Plasma Peptides of Breast Versus Ovarian Cancer

  • Striking agreement between the breast cancer plasma peptides and proteins discovered by LC-ESI-MS/MS with previous biomarkers from tumors, cell lines or body fluids by genetic or biochemical methods

Clinical Proteomics

View Publication

Blood Infection: The Plasma Peptides of Sepsis

  • Disease association variation in the processing of SAA1 in sepsis patients

Clinical Proteomics

View Publication

The Plasma Peptidome

  • Largest number of blood proteins identified to date
  • Ability to monitor ex vivo proteolysis of most human proteins, including interleukins, from blood

Clinical Proteomics

View Publication 

Oncology: The Plasma Peptides of Breast Versus Ovarian Cancer

  • Striking agreement between the breast cancer plasma peptides and proteins discovered by LC-ESI-MS/MS with previous biomarkers from tumors, cell lines or body fluids by genetic or biochemical methods

Clinical Proteomics

View Publication

Blood Infection: The Plasma Peptides of Sepsis

  • Disease association variation in the processing of SAA1 in sepsis patients

Clinical Proteomics

View Publication

Research & Publications

ELiMSA

Blinded Oncology Study 1: Analytical Advantage

  • Absolute sensitivity to detect attomole of PSA
  • Comparable sensitivity to RIA
  • 1000-fold more sensitive than electrochemical detectors

Journal of Proteomics

View Publication

Blinded Oncology Study 2: Predicate Agreement

  • Excellent agreement with, but more sensitive than the present gold standard commercial fourescent ELISA, or ECL-based detection of PSA from normal and prostatectomy samples

Analytical and Bioanalytical Chemistry

View Publication

Blinded Oncology Study 3: Clinical Advantage

  • Routine analysis of proteins over the complete range of physiological concentrations

Analytical Biochemistry

View Publication

https://yyzpharmatech.com/wp-content/uploads/2021/11/img-real-people-solutions.png
Enabling the Next Generation of Medicine

Partnering with
YYZ Pharmatech

  • YYZ was founded to enable & partner with visionary life science companies.
  • All YYZ technologies were built from inception to be scalable, licensable & transferable.
  • Currently seeking collaboration with industry partners on projects requiring breakthrough:
    1. Where novel low-abundance markers would progress drug development
    2. Where assay approaches are currently limited by sensitivity
bt_bb_section_bottom_section_coverage_image

Connect with Us

bt_bb_section_bottom_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Connect with us

Subscribe to our newsletter to receive the latest news and updates on YYZ.

[contact-form-7 404 "Not Found"]
https://yyzpharmatech.com/wp-content/uploads/2020/04/img-footer-map.png

Connect with us

Subscribe to our newsletter to receive the latest news and updates on YYZ.

[contact-form-7 404 "Not Found"]

Copyright ©2022. All Rights Reserved | Website Developed & Managed by GlobeSign

Copyright ©2022. All Rights Reserved | Website Developed & Managed by GlobeSign